These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 21536939)

  • 1. Individualized guidelines: the potential for increasing quality and reducing costs.
    Eddy DM; Adler J; Patterson B; Lucas D; Smith KA; Morris M
    Ann Intern Med; 2011 May; 154(9):627-34. PubMed ID: 21536939
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improving practice guidelines with patient-specific recommendations.
    Owens DK
    Ann Intern Med; 2011 May; 154(9):638-9. PubMed ID: 21536940
    [No Abstract]   [Full Text] [Related]  

  • 3. The cost-effectiveness of implementing a new guideline for cardiovascular risk management in primary care in the Netherlands.
    Kok L; Engelfriet P; Jacobs-van der Bruggen MA; Hoogenveen RT; Boshuizen HC; Verschuren MW
    Eur J Cardiovasc Prev Rehabil; 2009 Jun; 16(3):371-6. PubMed ID: 19305351
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estimated annual direct expenditures in the United States as a result of inappropriate hypertension treatment according to national treatment guidelines.
    Balu S
    Clin Ther; 2009 Jul; 31(7):1581-94. PubMed ID: 19695408
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Economics of suboptimal drug use: cost-savings of using JNC-recommended medications for management of uncomplicated essential hypertension.
    Xu KT; Moloney M; Phillips S
    Am J Manag Care; 2003 Aug; 9(8):529-36. PubMed ID: 12921230
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of a pharmacist-managed hypertension program on health system costs: an evaluation of the Study of Cardiovascular Risk Intervention by Pharmacists-Hypertension (SCRIP-HTN).
    Houle SK; Chuck AW; McAlister FA; Tsuyuki RT
    Pharmacotherapy; 2012 Jun; 32(6):527-37. PubMed ID: 22552863
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Population strategies to decrease sodium intake and the burden of cardiovascular disease: a cost-effectiveness analysis.
    Smith-Spangler CM; Juusola JL; Enns EA; Owens DK; Garber AM
    Ann Intern Med; 2010 Apr; 152(8):481-7, W170-3. PubMed ID: 20194225
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The impact of prevention on reducing the burden of cardiovascular disease.
    Kahn R; Robertson RM; Smith R; Eddy D
    Circulation; 2008 Jul; 118(5):576-85. PubMed ID: 18606915
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Hypertension and stroke: new publications in 2005].
    Schrader J
    MMW Fortschr Med; 2005 Nov; 147(46):40-2, 44. PubMed ID: 16358633
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [New treatment strategies for the management of hypertension].
    Reinhardt A; Linsel-Nitschke P; Schunkert H
    MMW Fortschr Med; 2009 Nov; 151(46):33-6. PubMed ID: 20043391
    [No Abstract]   [Full Text] [Related]  

  • 11. Impact of the 2014 expert panel recommendations for management of high blood pressure on contemporary cardiovascular practice: insights from the NCDR PINNACLE registry.
    Borden WB; Maddox TM; Tang F; Rumsfeld JS; Oetgen WJ; Mullen JB; Spinler SA; Peterson ED; Masoudi FA
    J Am Coll Cardiol; 2014 Dec; 64(21):2196-203. PubMed ID: 25447261
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Developing hypertension guidelines: an evolving process.
    Kotchen TA
    Am J Hypertens; 2014 Jun; 27(6):765-72. PubMed ID: 24572703
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of implementing new guidelines for treatment of hypertension in general practice.
    Richardson G; Godfrey L; Gravelle H; Watt I
    Br J Gen Pract; 2004 Oct; 54(507):765-71. PubMed ID: 15469676
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Towards a better yardstick: the choice of treatment thresholds in hypertension.
    McAlister FA; Laupacis A
    Can J Cardiol; 1998 Jan; 14(1):47-51. PubMed ID: 9487272
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Population impact of the 2017 ACC/AHA guidelines compared with the 2013 ESH/ESC guidelines for hypertension management.
    Vaucher J; Marques-Vidal P; Waeber G; Vollenweider P
    Eur J Prev Cardiol; 2018 Jul; 25(10):1111-1113. PubMed ID: 29637794
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Model-based simulation to explore the cost-effectiveness of following practice guidelines for triglyceride and low-density lipoprotein cholesterol control among patients with diabetes mellitus and mixed dyslipidemia.
    Sorensen SV; Frick KD; Wade A; Simko R; Burge R
    Clin Ther; 2009 Apr; 31(4):862-79. PubMed ID: 19446159
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Toward targeted hypertension screening guidelines.
    van Buuren S; Boshuizen HC; Reijneveld SA
    Med Decis Making; 2006; 26(2):145-53. PubMed ID: 16525168
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Generalizability of guidelines and physicians' adherence. Case study on the Sixth Joint National Commitee's guidelines on hypertension.
    Pedone C; Lapane KL
    BMC Public Health; 2003 Jul; 3():24. PubMed ID: 12873353
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stroke and coronary heart disease in treated hypertension -- a prospective cohort study over three decades.
    Almgren T; Persson B; Wilhelmsen L; Rosengren A; Andersson OK
    J Intern Med; 2005 Jun; 257(6):496-502. PubMed ID: 15910553
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The value of antihypertensive drugs: a perspective on medical innovation.
    Cutler DM; Long G; Berndt ER; Royer J; Fournier AA; Sasser A; Cremieux P
    Health Aff (Millwood); 2007; 26(1):97-110. PubMed ID: 17211019
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.